Analysts’ Viewpoint on Gout Therapeutics Market Scenario
Gout is a metabolic disorder caused by an increase in uric acid levels in the body, which leads to the development of gouty arthritis. Gout treatment necessitates both pharmacological and non-pharmacological measures. Newer drugs that target different inflammatory mediators, enzymes, or transporters are in various stages of clinical development. Several drugs have moderate-to-high evidence of benefit for pain relief in patients with acute gout. NSAIDs, colchicine, and glucocorticoids have long been used as prophylaxis when starting urate-lowering therapy (ULT) and to treat the inflammation of acute gout attacks. All of these are considered first-line treatments for acute gout, and combination therapy can be used in severe cases. Gout is becoming more common and poses a significant health risk. Despite the fact that gout treatment has been known since long, there are still many challenges in gout management. Increased investment in research and development programs by key players is expected to drive the global gout therapeutics market during the forecast period.
Gout is an inflammatory arthritic condition caused by the deposition of monosodium crystals (MSU) into the distal joints and peripheral tissues. Gout is a common form of inflammatory arthritis that is quite painful. It usually affects one joint at a time (often the big toe joint). There are times when symptoms get worse, known as flares, and times when there are no symptoms, known as remission.
Gout is a common and complex form of arthritis that can affect anyone. It is characterized by sudden, severe attacks of pain, swelling, redness, and tenderness in one or more joints, most often in the big toe. It usually occurs earlier in men than women. It generally occurs after menopause in women. Men can be three times more likely than women to get it because they have higher levels of uric acid most of their lives. Women reach these uric acid levels after menopause.
Gout treatment exist; however, therapy should be tailored for each person. Treatment choices depend on kidney function, other health issues, personal preferences, and other factors. Patients could need medications to lower their elevated blood uric acid levels that predispose to gout. Over time, increased uric acid levels in the blood could lead to deposits of urate crystals in and around the joints. These crystals can attract white blood cells, leading to severe, painful gout attacks and chronic arthritis.
Request a sample to get extensive insights into the Gout Therapeutics Market
Gout is the most common type of inflammatory arthropathy. According to several studies, its prevalence and incidence have increased in the last few decades. Hyperuricemia, genetic factors, dietary factors, alcohol consumption, metabolic syndrome, hypertension, obesity, diuretic use, and chronic renal disease are the risk factors for the development of gout.
Several studies have shown that gout management in primary care is suboptimal, which could contribute to rise in prevalence of clinically significant symptomatic gout. Obesity, diabetes, and hypertension were found to be common in gout patients in the U.K. and Germany. Age is also a risk factor; hence, population aging is likely to increase the incidence of gout. Complex cases of gout, particularly secondary gout, are becoming more common in hospital practice, with the rising prevalence of advanced chronic kidney disease and usage of diuretics and nephrotoxic drugs potentially driving the global gout therapeutics market size.
Gout incidence and prevalence increases with age, with prevalence reaching 11% to 13% and incidence reaching 0.4% in people over the age of 80. Gout is more common in racial minorities in the U.S., New Zealand Mori, Han Chinese, and some ethnic groups in Asia Pacific.
In terms of drug type, the nonsteroidal anti‐inflammatory drugs (NSAIDs) segment accounted for the largest gout therapeutic market share in 2021. NSAIDs are aspirin-like medications that can reduce inflammation and pain in joints and other tissues. NSAIDs, such as indomethacin (Indocin) and naproxen (Naprosyn), have become the treatment of choice for the majority of acute gout attacks. There is no evidence that one NSAID is superior to another. High doses of short-acting NSAIDs provide the quickest symptom relief. These medications could cause stomach upset, ulcers, or diarrhea; however, most people tolerate them well when used for a short period of time.
Urate-lowering drugs are utilized for the symptomatic treatment of gout arthritis, as a first line of therapy or in combination therapy. According to estimates, more than 2 million people in the U.S. take medication to decrease serum uric acid levels. Moreover, higher penetration of urate-lowering drugs compared to biologics into the gout therapeutics market for the treatment of people suffering from chronic or acute gout diseases propels the antihyperuricemic agents (urate-lowering drugs) segment.
Request a custom report on Gout Therapeutics Market
Based on distribution channel, the hospital pharmacies segment is projected to account for a dominant share of the global gout therapeutic market in 2021. The segment is anticipated to grow considerably from 2022 to 2031. Hospital pharmacies is expected to be the second-leading segment, in terms of market share, during the forecast period. The segment's large market share is attributed to the increase in geriatric population with moderate to severe gout arthritis requiring hospital pharmacy to purchase drugs.
The online pharmacies segment is likely to grow at a rapid pace during the forecast period. Increase in the number of online pharmacies and acceptance of several gout therapeutics as over-the-counter drugs in medical therapy to penetrate the pharmaceutical and the health care market are projected to augment the online pharmacies segment.
North America accounted for the largest share of the global gout therapeutics market in 2021. The region is projected to be a highly lucrative market during the forecast period, with high market attractiveness index. Increasing incidence of gout and rising burden of comorbidities in the U.S. are likely to propel the market in the region during the forecast period. Gout is the most common inflammatory arthritis in the country. Several studies have shown an increase in prevalence in the last few decades. There are more than nine million gout patients, and nearly a third of those patients are treated with oral urate-lowering therapies in the past 20 years. The number of people living with gout-related disability has risen steeply in the past few years.
The market in Asia Pacific is expected to grow at a rapid pace from 2022 to 2031. The incidence and prevalence of gout have been steadily increasing in the region, which has resulted in increased research & development activities in gout diagnosis and gout treatment.
The global gout therapeutics market is consolidated, with the presence of small number of leading players. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the leading players in the global gout therapeutics market. Takeda Pharmaceutical Company Limited, Teijin Pharma Limited, Novartis AG, Mylan N.V., MERCK & Co. Inc., Iroko Pharmaceutical LLC, Hikma Pharmaceuticals plc, Horizon Therapeutics plc, and Teva Pharmaceutical Industries Ltd. are the prominent players operating in the global gout therapeutics market.
Each of these players has been profiled in the gout therapeutics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 2.2 Bn |
|
Market Forecast Value in 2031 |
More than US$ 4.9 Bn |
|
Growth Rate (CAGR) |
8.4% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2020 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global gout therapeutics market was valued at US$ 2.2 Bn in 2021.
The global market is projected to reach more than US$ 4.9 Bn by 2031.
The global gout therapeutics market is anticipated to grow at a CAGR of 8.4% from 2022 to 2031.
Increase in incidence of gout and the link between alcohol consumption and gout.
North America is expected to account for major share of the global gout therapeutics market during the forecast period.
GlaxoSmithKline plc, Savient Pharmaceuticals, Takeda Pharmaceutical Company Ltd., Novartis AG, AstraZeneca plc, Merck & Co. Inc., Teijin Pharma Ltd., and Regeneron Pharmaceuticals.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Gout Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gout Therapeutics Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Global Skincare Drug Types Market
5.2. Key Industry Events (mergers, acquisitions, collaborations, approvals, etc.)
5.3. COVID-19 Impact Analysis
6. Global Gout Therapeutics Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Type, 2017–2031
6.3.1. NSAIDS
6.3.2. Colchicine
6.3.3. Corticosteroids
6.3.4. Urate-lowering Drugs
6.3.5. Biologics
6.4. Market Attractiveness Analysis, by Drug Type
7. Global Gout Therapeutics Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Distribution Channel, 2017–2031
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Gout Therapeutics Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Gout Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug Type, 2017–2031
9.2.1. NSAIDS
9.2.2. Colchicine
9.2.3. Corticosteroids
9.2.4. Urate-lowering Drugs
9.2.5. Biologics
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Type
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Gout Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Type, 2017–2031
10.2.1. NSAIDS
10.2.2. Colchicine
10.2.3. Corticosteroids
10.2.4. Urate-lowering Drugs
10.2.5. Biologics
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Type
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Gout Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Type, 2017–2031
11.2.1. NSAIDS
11.2.2. Colchicine
11.2.3. Corticosteroids
11.2.4. Urate-lowering Drugs
11.2.5. Biologics
11.3. Market Value Forecast, by Distribution Channel, 2017–2031
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Type
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Gout Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2017–2031
12.2.1. NSAIDS
12.2.2. Colchicine
12.2.3. Corticosteroids
12.2.4. Urate-lowering Drugs
12.2.5. Biologics
12.3. Market Value Forecast, by Distribution Channel, 2017–2031
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Type
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Gout Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Type, 2017–2031
13.2.1. NSAIDS
13.2.2. Colchicine
13.2.3. Corticosteroids
13.2.4. Urate-lowering Drugs
13.2.5. Biologics
13.3. Market Value Forecast, by Distribution Channel, 2017–2031
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Type
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2021
14.2.1. Takeda Pharmaceutical Company Limited
14.2.1.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.2.1.2. Product Portfolio
14.2.1.3. SWOT Analysis
14.2.1.4. Strategic Overview
14.2.1.5. Financial Overview
14.2.2. Teijin Pharma Limited
14.2.2.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.2.2.2. Product Portfolio
14.2.2.3. SWOT Analysis
14.2.2.4. Strategic Overview
14.2.2.5. Financial Overview
14.2.3. Novartis AG
14.2.3.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.2.3.2. Product Portfolio
14.2.3.3. SWOT Analysis
14.2.3.4. Strategic Overview
14.2.3.5. Financial Overview
14.2.4. Mylan N.V.
14.2.4.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.2.4.2. Product Portfolio
14.2.4.3. SWOT Analysis
14.2.4.4. Strategic Overview
14.2.4.5. Financial Overview
14.2.5. Horizon Pharma plc
14.2.5.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.2.5.2. Product Portfolio
14.2.5.3. SWOT Analysis
14.2.5.4. Strategic Overview
14.2.5.5. Financial Overview
14.2.6. Teva Pharmaceutical Industries Ltd.
14.2.6.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.2.6.2. Product Portfolio
14.2.6.3. SWOT Analysis
14.2.6.4. Strategic Overview
14.2.6.5. Financial Overview
14.2.7. Hikma Pharmaceuticals plc
14.2.7.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.2.7.2. Product Portfolio
14.2.7.3. SWOT Analysis
14.2.7.4. Strategic Overview
14.2.7.5. Financial Overview
14.2.8. Iroko Pharmaceuticals, LLC
14.2.8.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.2.8.2. Product Portfolio
14.2.8.3. SWOT Analysis
14.2.8.4. Strategic Overview
14.2.8.5. Financial Overview
14.2.9. MERCK & CO., Inc.
14.2.9.1. Company Overview (HQ, Business Segments, Employee Strengths)
14.2.9.2. Product Portfolio
14.2.9.3. SWOT Analysis
14.2.9.4. Strategic Overview
14.2.9.5. Financial Overview
List of Tables
Table 01: Global Gout Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 02: Global Gout Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 03: Global Gout Therapeutics Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 04: North America Gout Therapeutics Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 05: North America Gout Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 06: North America Gout Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 07: Europe Gout Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 08: Europe Gout Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 09: Europe Gout Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 10: Asia Pacific Gout Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 11: Asia Pacific Gout Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 12: Asia Pacific Gout Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Latin America Gout Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Latin America Gout Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 15: Latin America Gout Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 16: Middle East & Africa Gout Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Middle East & Africa Gout Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 18: Middle East & Africa Gout Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Gout Therapeutics Market Size (US$ Mn) and Distribution (%), by Region, 2017 and 2031
Figure 02: Global Gout Therapeutics Market Revenue (US$ Mn), by Drug Type, 2021
Figure 03: Global Gout Therapeutics Market Value Share, by Drug Type, 2021
Figure 04: Global Gout Therapeutics Market Value Share, by Distribution Channel, 2021
Figure 05: Global Gout Therapeutics Market Value Share, by Region, 2021
Figure 06: Global Gout Therapeutics Market Value (US$ Mn) Forecast, 2017–2031
Figure 07: Global Gout Therapeutics Market Value Share Analysis, by Drug Type, 2017 and 2031
Figure 08: Global Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2022-2031
Figure 09: Global Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 10: Global Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022-2031
Figure 11: Global Gout Therapeutics Market Value Share Analysis, by Region, 2017 and 2031
Figure 12: Global Gout Therapeutics Market Attractiveness Analysis, by Region, 2022-2031
Figure 13: North America Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 14: North America Gout Therapeutics Market Attractiveness Analysis, by Country, 2017–2031
Figure 15: North America Gout Therapeutics Market Value Share Analysis, by Country, 2017 and 2031
Figure 16: North America Gout Therapeutics Market Value Share Analysis, by Drug Type, 2017 and 2031
Figure 17: North America Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 18: North America Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 19: North America Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 20: Europe Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 21: Europe Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 22: Europe Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 23: Europe Gout Therapeutics Market Value Share Analysis, by Drug Type, 2017 and 2031
Figure 24: Europe Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 25: Europe Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 26: Europe Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 27: Asia Pacific Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 28: Asia Pacific Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 29: Asia Pacific Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 30: Asia Pacific Gout Therapeutics Market Value Share Analysis, by Drug Type, 2017 and 2031
Figure 31: Asia Pacific Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 32: Asia Pacific Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 33: Asia Pacific Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 34: Latin America Gout Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 35: Latin America Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 36: Latin America Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 37: Latin America Gout Therapeutics Market Value Share Analysis, by Drug Type, 2017 and 2031
Figure 38: Latin America Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 39: Latin America Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 40: Latin America Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 41: Middle East & Africa Gout Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 42: Middle East & Africa Gout Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 43: Middle East & Africa Gout Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 44: Middle East & Africa Gout Therapeutics Market Value Share Analysis, by Drug Type, 2017 and 2031
Figure 45: Middle East & Africa Gout Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 46: Middle East & Africa Gout Therapeutics Market Attractiveness Analysis, by Drug Type, 2022–2031
Figure 47: Middle East & Africa Gout Therapeutics Market Attractiveness Analysis, by Application, 2022–2031
Figure 48: Middle East & Africa Gout Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Gout Therapeutics Market
*86 figures and 60 tables includes